Letter to the Editor in response to the article "Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis"

被引：0
|
作者：
Farag, Youssef M. K. [1 ]
Zheng, Zihe [1 ]
Luo, Wenli [1 ]
机构：
[1] Akebia Therapeut Inc, 245 First St, Cambridge, MA 02142 USA
来源：
PHARMACOLOGICAL RESEARCH | 2021年 / 163卷
关键词：
D O I：
10.1016/j.phrs.2020.105213
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis
    Zheng, Qiyan
    Yang, Huisheng
    Sun, Luying
    Wei, Ruojun
    Fu, Xinwen
    Wang, Yahui
    Huang, Yishan
    Liu, Yu Ning
    Liu, Wei Jing
    [J]. PHARMACOLOGICAL RESEARCH, 2020, 159
  • [2] In response to "Title: Letter to the Editor in response to the article 'Efficacy and safety of HIF prolyl hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis"'
    Zheng, Qiyan
    Yang, Huisheng
    Liu, Yu Ning
    Liu, Wei Jing
    [J]. PHARMACOLOGICAL RESEARCH, 2021, 163
  • [3] Comparative effectiveness and acceptability of HIF prolyl-hydroxylase inhibitors versus for anemia patients with chronic kidney disease undergoing dialysis: a systematic review and network meta-analysis
    Huang, Qiong
    You, Minling
    Huang, Weijuan
    Chen, Jian
    Zeng, Qinming
    Jiang, Longfeng
    Du, Xiuben
    Liu, Xusheng
    Hong, Ming
    Wang, Jing
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [4] A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease
    Chen, Jun
    Shou, Xinyang
    Xu, Yanyan
    Jin, Lie
    Zhu, Chaoyong
    Ye, Xiaolan
    Mei, Ziwei
    Chen, Peipei
    [J]. AGING-US, 2023, 15 (06): : 2237 - 2274
  • [5] Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis
    Chen, Dinghua
    Niu, Yue
    Liu, Fei
    Yang, Yue
    Wang, Xue
    Li, Ping
    Chen, Xiangmei
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [6] Cardiac and Kidney Adverse Effects of HIF Prolyl-Hydroxylase Inhibitors for Anemia in Patients With CKD Not Receiving Dialysis: A Systematic Review and Meta-analysis
    Zheng, Qiyan
    Wang, Yahui
    Yang, Huisheng
    Sun, Luying
    Zhang, Pingna
    Zhang, Xueqin
    Guo, Jing
    Liu, Yu Ning
    Liu, Wei Jing
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2023, 81 (04) : 434 - +
  • [7] Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis
    Tian, Lei
    Wang, Mengdi
    Liu, Mengchao
    Pang, Yanyu
    Zhao, Jingwen
    Zheng, Bingjie
    Wang, Yutong
    Zhao, Wenjing
    [J]. RENAL FAILURE, 2024, 46 (01)
  • [8] Efficacy and safety of vadadustat compared to darbepoetin alfa on anemia in patients with chronic kidney disease: a meta-analysis
    Qiong Huang
    Zhenyi Liao
    Xiaoyan Liu
    Yun Xia
    Jing Wang
    [J]. International Urology and Nephrology, 2023, 55 : 325 - 334
  • [9] Efficacy and safety of vadadustat compared to darbepoetin alfa on anemia in patients with chronic kidney disease: a meta-analysis
    Huang, Qiong
    Liao, Zhenyi
    Liu, Xiaoyan
    Xia, Yun
    Wang, Jing
    [J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2023, 55 (02) : 325 - 334
  • [10] Letter to the editor regarding 'A systemic review and meta-analysis on the efficacy and safety of ferumoxytol for anemia in chronic kidney disease patients'
    Li, Linqiang
    Feng, Huiqin
    [J]. RENAL FAILURE, 2023, 45 (01)
12345